Subtype
Clear Cell Renal Cell Carcinoma
CI-CAN-00004976CCRCCExplore in graph →
114 active trials2 approved drugs19 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004976CCRCCExplore in graph →
Clinical trials
247 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (39)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07043608 | Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases(ZAMBONI) | recruiting | Phase 2 | 20 | Kelly Fitzgerald, MDOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT06942104 | Imaging of Solid Tumors Using 18F-TRX | recruiting | Phase 1 | 56 | Rahul AggarwalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06049576 |
| Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma |
| active not recruiting |
| Phase 1 |
| 31 |
| City of Hope Medical CenterOTHER |
| 1 |
| Jul 22, 2026 |
| clinicaltrials |
| NCT07077083 | CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC(CAIX PET/CT) | not yet recruiting | Phase 2 | 10 | Massachusetts General HospitalOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07128680 | Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer | recruiting | Phase 1 | 33 | City of Hope Medical CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03972657 | A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors | recruiting | Phase 1 / Phase 2 | 345 | Regeneron PharmaceuticalsINDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT05520099 | Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)(ELEPHAS-02) | active not recruiting | — | 416 | ElephasINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06447103 | An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer | recruiting | Phase 2 | 91 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07383441 | Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer | recruiting | Phase 3 | 718 | SWOG Cancer Research NetworkNETWORK | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07037004 | Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery | recruiting | Phase 2 | 62 | City of Hope Medical CenterOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT06026410 | KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors(FIT-001) | recruiting | Phase 1 | 300 | Kura Oncology, Inc.INDUSTRY | 5 | Jun 8, 2026 | clinicaltrials |
| NCT07510334 | VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma | recruiting | Phase 2 | 18 | Mayo ClinicOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06783348 | Radiopharmaceutical Treatment of Advanced Kidney Cancer(RENALUT) | recruiting | Phase 2 | 48 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Jun 4, 2026 | clinicaltrials |
| NCT03092856 | Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer | active not recruiting | Phase 2 | 62 | University of Southern CaliforniaOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT02210117 | Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery | active not recruiting | Early Phase 1 | 104 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06949215 | 68Ga-NYM096 PET/ CT for the Detection of ccRCC in Presurgical Patients With Complex Cystic Renal Leision(NYCRCCL) | recruiting | Phase 2 | 70 | Peking Union Medical College HospitalOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07023432 | Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC) | recruiting | Phase 2 | 78 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07602101 | Neoadjuvant PD-L1 Inhibitor Plus Anlotinib for Kidney Preservation in Complex Renal Cell Carcinoma | not yet recruiting | Phase 2 | 33 | RenJi HospitalOTHER | 0 | May 22, 2026 | clinicaltrials |
| NCT04388852 | DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers | active not recruiting | Phase 1 | 65 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT06035224 | Cadonilimab (AK104) Plus Lenvatinib in Previously Immunotherapy-Treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma | active not recruiting | Phase 2 | 28 | RenJi HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07557225 | 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors | recruiting | N/A | 200 | Peking University First HospitalOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06852638 | CD70-targeted immunoPET Imaging of Malignant Cancers | recruiting | Phase 2 | 300 | RenJi HospitalOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT06195150 | Overtaking Intra and Inter Tumoral Heterogeneity In Von Hippel-Lindau Related Renal Cancer(ITHORinVHL) | active not recruiting | — | 3 | IRCCS San RaffaeleOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT07571551 | Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell Carcinoma(TRIPLE-PATH) | recruiting | Phase 2 | 75 | Jinling Hospital, ChinaOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT07578025 | Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy | not yet recruiting | Phase 2 | 34 | City of Hope Medical CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04053855 | Evaluation of Urinary Exosomes Presence From Clear Cell Renal Cell Carcinoma(PEP-C) | recruiting | — | 100 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04022343 | Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer | active not recruiting | Phase 2 | 22 | Emory UniversityOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT06413680 | A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body(BrILliance) | recruiting | Phase 1 / Phase 2 | 240 | Regeneron PharmaceuticalsINDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT03682289 | Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors | active not recruiting | Phase 2 | 83 | Rahul AggarwalOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT03401788 | A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004) | active not recruiting | Phase 2 | 50 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 4 | Apr 13, 2026 | clinicaltrials |
| NCT07197580 | Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC(LUTEON) | recruiting | Phase 3 | 40 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07488572 | Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study | enrolling by invitation | Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT06349642 | Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform(ELEPHAS-04) | recruiting | — | 324 | Mayo ClinicOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT07460206 | Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment(PRELUDE) | not yet recruiting | Phase 2 | 108 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 0 | Mar 10, 2026 | clinicaltrials |
| NCT05122546 | CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer | active not recruiting | Phase 1 | 31 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT07223541 | Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma(LAG-BOOST) | recruiting | Phase 2 | 72 | University of OklahomaOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT01684397 | Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer | active not recruiting | Phase 1 / Phase 2 | 51 | Roswell Park Cancer InstituteOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07243067 | Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer | not yet recruiting | — | 300 | Mayo ClinicOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06964958 | 177LuPSMA in Renal Cell Carcinoma(LASER) | active not recruiting | Phase 2 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT07389629 | Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC | recruiting | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07386158 | Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC | recruiting | Phase 2 | 21 | Sun Yat-sen UniversityOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT04645680 | Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy(DIET) | active not recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT05239533 | Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer | active not recruiting | Phase 2 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07332923 | Predicting HIF-2α Levels in Clear Cell Kidney Cancer Using Machine Learning | active not recruiting | — | 500 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT05856981 | Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors | recruiting | Phase 1 | 130 | Sairopa B.V.INDUSTRY | 3 | Dec 17, 2025 | clinicaltrials |
| NCT05363631 | Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab | active not recruiting | Phase 1 / Phase 2 | 55 | Mohammed MilhemOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT04989959 | [18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma | recruiting | Phase 1 | 35 | Orhan Kemal OzOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT07218692 | RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy | not yet recruiting | Phase 2 | 35 | City of Hope Medical CenterOTHER | 1 | Oct 20, 2025 | clinicaltrials |
| NCT03438708 | Prior Axitinib as a Determinant of Outcome of Renal Surgery(PADRES) | active not recruiting | Phase 2 | 22 | University of California, San DiegoOTHER | 1 | Oct 2, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Jul 27, 2026source: clinicaltrials